Emmanouil Panagiotidis, Vasiliki Fragkiadaki, Nikolaos Papathanasiou, Charalampos Kypraios, Evangelos Liatsikos, Athanasios Klampatsas, Anna Paschali, Dimitrios Exarhos, Foteini Zarokosta, Vasiliki Chatzipavlidou, Dimitrios Apostolopoulos, Ioannis Datseris
OBJECTIVES: This prospective, multicenter, open-label, randomized, crossover trial study was to evaluate the diagnostic performance of 18F-PSMA-1007 (PSMA) vs. 18F-Choline PET/CT (FCH) in prostate cancer (PCa) patients (pts) with biochemical recurrence (BCR). METHODS: One hundred eighty-six pts, who have undergone primary definitive treatment for PCa with BCR, were recruited to this prospective study. All pts underwent one PSMA and one FCH PET/CT examination in randomized order within a time frame of 8 days and were followed up for at least 6 months (182 ± 10 days)...
December 1, 2023: Nuclear Medicine Communications